NITI Aayog's roadmap aims to expand India's bioeconomy from $195.3 billion in 2025 to $2.6 trillion by 2047, backed by a ₹5,000 crore fund, mission‑mode execution and regulatory overhaul. The plan seeks to position India among the top three biotech powers worldwide by 2035.

Key Takeaways

  • ₹5,000 crore BioEconomy Growth Fund to bridge the sector's "valley of death"
  • Six national biotech missions slated for launch by 2035
  • Bioeconomy projected to grow from $195.3 bn (2025) to $2.6 tn (2047)

New Delhi (July 16, 2026) – NITI Aayog released a comprehensive report titled “Roadmap for Building India as a Leading BioEconomy Powerhouse by 2035,” outlining an ambitious blueprint to catapult India into the top three global biotechnology powers by 2035. Central to the strategy is a ₹5,000 crore (≈ $600 million) BioEconomy Growth Fund, a dedicated Production‑Linked Incentive (PLI) scheme for biomanufacturing, and six national biotechnology missions.

Strategic Shift and Vision

The report urges India to move beyond the broad‑brush Biotechnology for Economy, Environment and Employment (BioE3) policy and adopt a mission‑mode execution model. By pairing fresh financing, regulatory reforms, and cross‑ministerial governance, the plan targets expanding the bioeconomy from $195.3 billion in 2025 to $691 billion by 2035 and a staggering $2.6 trillion by 2047, creating over 30 million high‑value jobs.

Fund Architecture and Objectives

The ₹5,000 crore fund is designed as blended finance, offering equity‑risk instruments, viability‑gap funding, and infrastructure support for biomanufacturing, advanced therapeutics, synthetic biology, fermentation technologies, and diagnostics. Its primary goal is to close the “valley of death” – the gap between proof‑of‑concept research and commercial‑scale production.

Six National BioMissions

Specific missions include GeneIndia (affordable gene and cell therapies), AgriBio 2.0 (climate‑resilient gene‑edited crops), BioX Foundry (commercialising synthetic biology), One Health Grid (integrated surveillance of infectious diseases and antimicrobial resistance), Marine Biotechnology (seaweed cultivation and marine bio‑products), and BioPharmaNext (positioning India as a hub for biologics, biosimilars and AI‑driven drug discovery).

Institutional Framework

To coordinate the rollout, the roadmap proposes new bodies such as an Empowered Committee on National BioMissions, a National BioData Council for health‑data governance, a BioEconomy Investment and Policy Forum, and a BioIP and Innovation Evaluation Agency to accelerate commercialisation of biotech IP.

Long‑Term Outlook

By treating biotechnology as critical national infrastructure—on par with digital public infrastructure and energy systems—the plan envisions integrating AI, robotics, computational biology and automated bio‑foundries to cut research timelines and boost global competitiveness. Successful implementation will hinge on streamlined regulatory pathways for emerging therapies and strong public‑private partnerships.